Controlled release delivery system for nasal applications and method of treatment
AssigneeMattern Pharma AG
InventorClaudia Mattern
Life of this patent
Estimating the term…
Abstract
This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Claims55
A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of a testosterone gel formulation comprising
- a) testosterone;
- b) at least one lipophilic or partly lipophilic carrier;
- and
- c) a compound or a mixture of compounds having surface tension decreasing activity.
A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of a testosterone gel formulation comprising
- a) testosterone;
- b) at least one lipophilic or partly lipophilic carrier in an amount from about 60% to about 98% by weight of the testosterone gel formulation;
- c) a compound or a mixture of compounds having surface tension decreasing activity in an amount from about 1% to about 20% by weight of the testosterone gel formulation;
- and
- d) a viscosity regulating agent in an amount from about 0.5% to about 10% by weight of the testosterone gel formulation.
A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of a testosterone gel formulation comprising
- a) testosterone;
- b) castor oil in an amount from about 60% to about 98% by weight of the testosterone gel formulation;
- c) an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides in an amount from about 1% to about 20% by weight of the testosterone gel formulation;
- and
- d) colloidal silicone dioxide in an amount from about 0.5% to about 10% by weight of the testosterone gel formulation.
Dependencies are inferred from the claim text.